CCAR-066 is under clinical development by Janssen Biotech and currently in Phase I for Follicular Lymphoma. According to GlobalData, Phase I drugs for Follicular Lymphoma have a 78% phase transition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback